Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma.

Franziska K KrebsEmily R TrzeciakSophia ZimmerDeniz ÖzistanbulluHeidrun Mitzel-RinkMarkus MeissnerStephan GrabbeCarmen LoquaiAndrea Tuettenberg

Published in: Cancer medicine (2021)

Our study demonstrated that the observed immune signature in the peripheral blood of melanoma patients prior to treatment could identify responders as well as non-responders that benefit from ICI immunotherapies.

Keyphrases

peripheral blood
ejection fraction
newly diagnosed
dna damage
prognostic factors
cell cycle
patient reported outcomes